Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report.
Scleromyxoedema is a rare disease with a progressive and disabling course involving dermal deposition of mucin and fibroblast proliferation; it is characterized clinically by a diffuse papular eruption, skin thickening, oedema and decreased skin flexibility, especially of the face and hands. Current therapy options are based on evidence from a limited number of case reports. The clinical manifestations and treatment of a 64-year-old man affected by scleromyxoedema with severe skin involvement of the face, arms and hands, decreased mouth opening and hypomotility of the fingers are reported. Dysphagia, asthenia and immunoglobulin G lambda monoclonal gammopathy were also present. Previous treatment with topical and systemic corticosteroids, psoralen plus ultraviolet A radiation therapy, plasmapheresis, extracorporeal photochemotherapy, hydroxychloroquine and cyclophosphamide had been unsuccessful. Treatment with intravenous immunoglobulins at a dosage of 2 g/kg monthly was started. Considerable improvements were observed after seven cycles of therapy, with recovery of skin elasticity, an increase in facial mimic movement, restoration of joint function and improvement in the modified Rodnan score. There were no observed side-effects. The patient remains in remission on monthly maintenance intravenous immunoglobulins, 2 years after initial treatment.
Dermatology Unit, Department of Head and Neck Surgery, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Federica
F
Arginelli
Dermatology Section, University of Genoa and San Martino University Hospital, Genoa, Italy.
Franco
F
Rongioletti
Department of Medicine, University of Verona, Verona, Italy.
Giampiero
G
Girolomoni
Dermatology Unit, Department of Head and Neck Surgery, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Giovanni
G
Pellacani
Dermatology Unit, Department of Head and Neck Surgery, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Davide
D
Guardoli
Dermatology Unit, Department of Head and Neck Surgery, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy a.conti.dermo@gmail.com.
Andrea
A
Conti
High-dose intravenous immunoglobulin; modified Rodnan score; scleromyxoedema
J Am Acad Dermatol. 2013 Jul;69(1):66-72
23453242
J Invest Dermatol. 1953 Mar;20(3):213-36
13044990
Indian J Dermatol Venereol Leprol. 2010 Sep-Oct;76(5):592
20827020
J Rheumatol. 1993 Nov;20(11):1892-6
8308774
Br J Dermatol. 2007 Nov;157(5):1058-60
17854360
Int Immunopharmacol. 2006 Apr;6(4):535-42
16504916
J Am Acad Dermatol. 2001 Feb;44(2):273-81
11174386
Semin Cutan Med Surg. 2006 Jun;25(2):100-4
16908401
J Eur Acad Dermatol Venereol. 2005 Jul;19(4):462-5
15987294
J Cutan Pathol. 2012 May;39(5):508-17
22515222
J Rheumatol. 1995 Jul;22(7):1281-5
7562759
J Am Acad Dermatol. 2007 Nov;57(5):890-1
17939940
J Am Acad Dermatol. 2009 Jun;60(6):1037-41
19249127
Acta Dermatovenerol Alp Pannonica Adriat. 2010 Dec;19(4):15-9
21390475
J Eur Acad Dermatol Venereol. 2007 Apr;21(4):553-4
17373996
Eur J Dermatol. 2010 Nov-Dec;20(6):852-3
20977988